Compare AUBN & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUBN | ICCC |
|---|---|---|
| Founded | 1907 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.8M | 75.8M |
| IPO Year | 1996 | 1995 |
| Metric | AUBN | ICCC |
|---|---|---|
| Price | $25.45 | $9.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.4K | ★ 20.1K |
| Earning Date | 04-28-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | 13.66 | ★ 53.85 |
| EPS | ★ 0.63 | 0.21 |
| Revenue | $619,000.00 | ★ $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $42.11 | $47.10 |
| Revenue Growth | 0.81 | ★ 51.64 |
| 52 Week Low | $21.60 | $4.52 |
| 52 Week High | $29.00 | $10.75 |
| Indicator | AUBN | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 71.26 | 50.90 |
| Support Level | $24.00 | $9.27 |
| Resistance Level | $27.76 | $10.75 |
| Average True Range (ATR) | 0.40 | 0.33 |
| MACD | 0.14 | -0.05 |
| Stochastic Oscillator | 98.13 | 36.67 |
Auburn National Bancorp Inc is a bank holding company registered with the Board of Governors of the Federal Reserve System (the Federal Reserve). As a bank holding company, the Company may diversify into a broader range of financial services and other business activities than are currently permitted to the Bank under applicable laws and regulations. The holding company structure also provides greater financial and operating flexibility than is presently permitted to the Bank. The Company's business is conducted through the Bank and its subsidiaries. Although it has no immediate plansto conduct any other business, the Company may engage directly or indirectly in several activities closely related to banking permitted by the Federal Reserve.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.